Post-transplant autoimmunity in a child: a lupus-like syndrome emerging in the context of chronic graft-versus-host disease.

Authors

Bengisu Menentoğlu, Selen Duygu Arık, Salih Güler, Deniz Tuğcu, Zeynep Karakas, Nuray Aktay Ayaz

Published in

The Turkish journal of pediatrics. Volume 68. Issue 3. Pages 539-546. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

Autoimmune manifestations are increasingly recognized as late complications following hematopoietic stem cell transplantation (HSCT), particularly in association with chronic graft-versus-host disease (cGvHD). However, the occurrence of systemic lupus erythematosus (SLE)-like features remains extremely rare, especially in pediatric patients. Understanding the mechanisms underlying such manifestations, including the role of mixed chimerism, is important for early recognition and management.
We report the case of a girl with thalassemia major who underwent HSCT from a fully matched unrelated donor at the age of six years. Her early post-transplant course was complicated by gastrointestinal cGvHD, followed by autoimmune hemolytic anemia and arthritis, which responded to corticosteroids and methotrexate. Four years post-HSCT, she developed a lupus-like syndrome characterized by malar rash, serositis, cytopenias, arthritis, high-titer antinuclear antibodies (ANA), elevated anti-double-stranded DNA (anti-dsDNA) antibodies, and low complement levels, fulfilling the American College of Rheumatology classification criteria for SLE. At the time of symptom onset, mixed chimerism was documented, with a notable proportion of recipient-derived lymphocytes. Treatment with mycophenolate mofetil and hydroxychloroquine led to rapid clinical and laboratory improvement.
This case illustrates the evolving nature of post-transplant immune dysregulation and suggests that declining donor chimerism may contribute to the reactivation of autoreactive lymphocytes, leading to atypical autoimmune manifestations. In pediatric patients presenting with unusual post-transplant symptoms, careful clinical assessment and immune monitoring may aid in timely diagnosis. Individualized immunosuppressive therapy can facilitate symptom control and support favorable long-term outcomes.

PMID:
42497439
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.